TP53 and neoplasm: It was reported that co-appearing genomic variations in the STK11/LKB1 (KL) and TP53 (KP) tumor suppressor genes modify subgroups of KRAS-mutant LUAC with distinct biology, immune profiles, and therapeutic vulnerabilities (218).